^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    4d
    Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (ChiCTR2500112673)
    P=N/A, N=316, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University
    New trial
    4d
    A phase II clinical Trial on the efficacy and safety of TQC3721 inhalation powder (ChiCTR2500112449)
    P2, N=195, Not yet recruiting, West China Hospital, Sichuan University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd
    New P2 trial
    4d
    Safety and Efficacy of Levosimendan for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial (ChiCTR2500110769)
    P4, N=100, Recruiting, the First Hospital of Jilin University.; the First Hospital of Jilin University. | Not yet recruiting --> Recruiting
    Enrollment open
    13d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Cairo University | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Cairo University
    New trial
    21d
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Eyevinal (ibudilast)
    26d
    A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P2 trial
    26d
    A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=33, Completed, Verona Pharma plc | Active, not recruiting --> Completed
    Trial completion
    28d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    Effect of levosimendan on plasma intestinal barrier factors in heart failure patients with reduced ejection fraction. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban)
    Levosimendan not only improves HF and gastrointestinal symptoms in hospitalized patients with acute exacerbation of HFrEF but also reduces plasma intestinal barrier factor levels. These effects may be associated with decreased plasma proinflammatory cytokines and increased anti-inflammatory cytokines after treatment, potentially involving IL-17 and TNF signaling pathways.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL17A (Interleukin 17A)
    1m
    The Effect of Cilostazol on Rheumatoid Arthritis Patients (clinicaltrials.gov)
    P2/3, N=70, Completed, Ain Shams University | Active, not recruiting --> Completed
    Trial completion
    |
    leflunomide
    2ms
    LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (clinicaltrials.gov)
    P3, N=540, Recruiting, Tenax Therapeutics, Inc.
    New P3 trial